Business Wire

Veracode Joins the Wiz Integration Network (WIN) to Eliminate Application-to-Cloud Security Blind Spots

22.7.2025 13:50:00 CEST | Business Wire | Press Release

Share

Veracode, a global leader in application risk management, today announced a partnership with leading cloud security provider, Wiz, joining the Wiz Integration (WIN) platform. The alliance enhances WIN by bringing the power of Veracode Risk Manager (VRM) to the partner ecosystem, enabling customers to seamlessly integrate Wiz and Veracode solutions into their existing workflows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250722633276/en/

The sheer volume and variety of vulnerability data can put pressure on even the most mature organizations. Veracode Risk Manager is an Application Security Posture Management (ASPM) solution designed to address this challenge by unifying risk from code to cloud, and automating prioritization and remediation to help security teams resolve critical flaws faster. With VRM connectors—connectors to third-party findings and asset sources—security teams get a consolidated view of risk across the entire software development lifecycle. These connectors ingest Veracode’s static, dynamic, and software composition analysis findings alongside issues uncovered by third-party tools, like Wiz, to help security teams trace root causes, prioritize risk, and remediate accordingly.

“Security teams are overwhelmed—not by a lack of data, but by too much of it, spread across too many disconnected tools,” said Derek Maki, Head of Product at Veracode. “By integrating Wiz’s deep cloud security findings directly into Veracode Risk Manager and correlating with Veracode application security testing detections, we’re giving security teams a clearer, faster, and prioritized view of risk so they can take immediate action.”

WIN enables Wiz and Veracode to share prioritized security findings with context, including inventory, vulnerabilities, issues, and configuration findings. Mutual customers receive the following benefits:

  • Smarter, more accurate risk prioritization: Wiz’s findings feed directly into Veracode Risk Manager, enhancing its scoring model and enabling more accurate prioritization of security issues based on real-time, contextual risk data.
  • Less noise, less burnout: By aggregating all risk data and applying the right context and prioritization, the integration helps security teams focus on the most critical issues, reducing alert fatigue and improving operational efficiency.
  • Certified, reliable integration: A rigorous certification process ensures the connector between Wiz and VRM is reliable, consistent, and jointly supported. Customers can trust that data flows correctly and that both teams are equipped to troubleshoot any issues that arise.

The combined value of these two offerings will streamline security for organizations that are on a cloud journey, regardless of where they may be on that journey.

“By bringing Veracode into the WIN ecosystem, we’re expanding the power of cloud-native context to help organizations connect the dots between application and cloud risk,” says Oron Noah, Vice President of Product Extensibility & Partnerships at Wiz.

WIN enables a cloud security operating model through which security and cloud teams work collaboratively to understand and control risks across their Continuous integration/Continuous Delivery (CI/CD) pipeline. Through the partnership, Wiz and Veracode are setting the industry standard in integrated solution strategy to optimize operational efficiency.

Current Veracode Risk Manager customers can enable the Wiz connector today through the Wiz Integrations Page. For a personalized demo of how this integration can transform an organization’s application security program, visit https://www.veracode.com/get-your-personalised-veracode-solution-demo/.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, Malicious Package Detection, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.

Copyright © 2025 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands, or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250722633276/en/

Contacts

Press and Media Contacts:
Katy Gwilliam
Head of Global Communications, Veracode
kgwilliam@veracode.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye